Fiche du document
- doi: 10.1038/s41571-020-00447-z
- issn: 1759-4774
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41571-020-00447-z
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33293629
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1759-4782
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7A911714966A2
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
TherapyCiter ce document
M. Weller et al., « EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. », Serveur académique Lausannois, ID : 10.1038/s41571-020-00447-z
Métriques
Partage / Export
Résumé
In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy - Not Officially WHO (cIMPACT-NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.